Overview

Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

The goal of this prospective study is to assess the overall mortality (whether related to relapse/progression or toxicity - TRM-) at one year after allogeneic stem cell transplantation prepared by a so-called reduced-toxicity "submyeloablative" conditioning regimen in patients with hematological malignancies.

Phase:

Phase 2

Details

Lead Sponsor:

Nantes University Hospital

Treatments:

Busulfan
Fludarabine
Thymoglobulin